Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies

21 Feb 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer-related Molecular Pathways
Share to Sarcoma Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30792212
DOI: 10.3324/haematol.2018.205302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignanciesPMID 30792212Read ↗

TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment.Semantic proximity Read ↗

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.Semantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

Haematological cancer: TP53 mutations sensitize to decitabine.Semantic proximity Read ↗

Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.Semantic proximity Read ↗

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.Semantic proximity Read ↗

Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution.Semantic proximity Read ↗

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.Semantic proximity Read ↗

Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.Semantic proximity Read ↗

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.Semantic proximity Read ↗

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation blockSemantic proximity Read ↗

Detection of TP53 mutations by immunohistochemistry in acute myeloid leukemia varies with interpreter expertise and mutation status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.